caa a22 4500 445334479 CHVBK 20180317142749.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1245/s10434-011-1698-z doi (NATIONALLICENCE)springer-10.1245/s10434-011-1698-z Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast Cancer [Elektronische Daten] [Jessica Partin, Eleftherios Mamounas] Background: The development of multigene assays has proved useful in the clinical management of early-stage breast cancer. The 21-gene recurrence score (RS) assay has been shown to quantify risk of distant recurrence and predict chemotherapy benefit in node-negative and node-positive, estrogen-receptor (ER)-positive breast cancer patients. Small, single-institution series have shown that, compared with standard clinicopathologic criteria, use of RS significantly affects adjuvant chemotherapy recommendations. Methods: We performed a retrospective review of RS use and its effect on chemotherapy recommendations in node-negative, ER-positive breast cancer patients at a tertiary care teaching hospital. Patient and tumor characteristics and adjuvant treatment information were obtained on 183 patients with RS results between January 2004 and October 2009. Risk categories were assigned based on the RS and on standard clinicopathologic criteria according to guidelines from NCCN, St. Gallen, and Adjuvant!. Results: A total of 14 patients were excluded for negative ER status (n=2), insufficient data (n=4), inclusion in TAILORx trial (n=7), and recurrent breast cancer (n=1), leaving 169 patients in the cohort. RS use increased 3-fold over the study period (from 18% in 2004 to 50% in 2009). Tumor grade, ER status, and PR status were significantly correlated with RS category. Overall concordance between RS and NCCN, St. Gallen, and Adjuvant! was 10, 48, and 50%, respectively. Depending on the guideline used for comparison, adjuvant therapy recommendations changed with the addition of the RS in 27-74% of cases. Conclusions: RS use is increasing, and the assay significantly reduced adjuvant chemotherapy utilization in node-negative, ER -positive breast cancer patients. Society of Surgical Oncology, 2011 Partin Jessica Akron General Medical Center, Akron, OH, USA aut Mamounas Eleftherios Aultman Health Foundation, Canton, OH, USA aut Annals of Surgical Oncology Springer-Verlag 18/12(2011-11-01), 3399-3406 1068-9265 18:12<3399 2011 18 10434 https://doi.org/10.1245/s10434-011-1698-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1698-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Partin Jessica Akron General Medical Center, Akron, OH, USA aut NATIONALLICENCE 700 1- Mamounas Eleftherios Aultman Health Foundation, Canton, OH, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/12(2011-11-01), 3399-3406 1068-9265 18:12<3399 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer